Printer Friendly

GLOBAL HEALTH SCIENCES FUND REPORTS EARNINGS AND HOLDINGS

 GLOBAL HEALTH SCIENCES FUND REPORTS EARNINGS AND HOLDINGS
 NEW YORK, March 13 /PRNewswire/ -- The Global Health Sciences Fund (NYSE: GHS) is a closed-end, diversified management investment company seeking capital appreciation through investments primarily in equity securities of United States and foreign companies principally engaged in the development, production or distribution of health science products or services. Today, the fund announced its performance for the period Jan. 20, 1992 (commencement of investment operations) to Jan. 31, 1992, and it most recent holdings.
 During the period ended Jan. 31, 1992, the fund's net investment income was $126,749 equal to $0.006 per share. Net realized and unrealized gains were $761,091 equal to $0.038 per share. The fund's total net assets at Jan. 31, 1992, were $279,362,780, and net asset value per share was $13.96 based on 20,007,200 shares outstanding.
 On March 6, 1992, total net assets of the fund were $275,549,674, and the net asset value per share was $13.44 based on 20,507,200 shares outstanding. The March 6 closing price of the fund's shares on the New York Stock Exchange was $13.63. Of the fund's $275.5 million in net assets, 52.2 percent was invested in equities (2.4 percent in foreign equities), 1.4 percent in fixed income securities and 38.4 percent in short term securities. Other assets in excess of liabilities accounted for the remaining 8.0 percent of total net assets.
 The fund's equity investments at March 6, 1992, were in the following industries: pharmaceuticals (21.6 percent of net assets); health care and delivery (13.5 percent); medical devices and supplies (9.3 percent); selected biotech (7.0 percent); miscellaneous (0.8 percent).
 As of March 6, 1992, the fund's ten largest common stock holdings (in descending order), representing 33.18 percent of net assets, were in:
 -- Schering Plough Corporation
 -- Bristol Myers Squibb Company
 -- Merck and Company, Inc.
 -- Baxter International, Inc.
 -- Hospital Corp. of America
 -- Synergen Inc.
 -- T2 Med Inc.
 -- Smithkline Beecham PLC
 -- Novo Nordisk A.S.
 -- Meditrust
 The fund's investment adviser is INVESCO Trust Company, a wholly- owned subsidiary of INVESCO MIM PLC. To receive a copy of the fund's propectus, please call 800-528-8675.
 -0- 5/13/92
 /CONTACT: Glen A. Payne, secretary of INVESCO Trust Company, 800-528-8675, or Michael LeSeur, 212-713-2707, for Global Health Sciences Fund/
 (GNS) CO: Global Health Sciences Fund ST: New York IN: FIN SU: ERN


KD -- NY062 -- 7984 03/13/92 17:42 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 13, 1992
Words:418
Previous Article:POWELL INDUSTRIES ANNUAL STOCKHOLDERS' MEETING
Next Article:MOODY''S CONFIRMS Aa RATING ON LOS ANGELES, CALIFORNIA DEPARTMENT OF WATER AND POWER ELECTRIC REVENUE BONDS
Topics:


Related Articles
GLOBAL HEALTH SCIENCES FUND INITIAL PUBLIC OFFERING
GLOBAL HEALTH SCIENCES FUND INITIAL PUBLIC OFFERING
THE GLOBAL HEALTH SCIENCES FUND REPORTS EARNINGS AND HOLDINGS
THE GLOBAL HEALTH SCIENCES FUND REPORTS EARNINGS AND HOLDINGS
On the mend.
Be open to closed-end funds.
INVESCO Global Health Sciences Fund Monthly Update through October 31, 2000.
INVESCO Global Health Sciences Fund - Monthly Update Through April 30, 2001.
HEALTH STOCKS CONTINUE TOWARD RECORD RETURNS.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters